Heron Therapeutics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $32.49. Which is the better fit depends on your goals.
| HRTX | TMF | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.96 | $44.14 |
52-Week Low | $0.39 | $31.85 |
Enterprise Value | $189.36M | — |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $32.66, down 2.07% on the day, reflecting a bearish technical trend with moving averages signaling sell pressure. The fund provides 3x daily leveraged exposure to long-term U.S. Treasury bonds, making it highly sensitive to interest rate movements. Recent news highlights its significant long-term decline, with a $10,000 investment five years ago now worth approximately $1,527, underscoring the risks of daily leverage reset in volatile markets.
The outlook for TMF hinges on the direction of long-term bond yields and Federal Reserve policy. While some analysts see potential at the lower end of the trading range, the fund's structure makes it unsuitable for long-term holding due to volatility decay. Key risks include rising interest rates, inflation expectations, and the inherent leverage mechanism that amplifies losses. It remains a high-risk, tactical instrument for short-term traders.
Trailing returns across standard periods
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →